Navigation Links
Autism Speaks creates Delivering Scientific Innovation for Autism LLC
Date:10/25/2012

NEW YORK, N.Y. (October 25, 2012) Autism Speaks, the world's leading autism science and advocacy organization, today announced the formation of Delivering Scientific Innovation for Autism (DELSIA) an independent not-for-profit affiliate of Autism Speaks that will work directly with for-profit sector partners to stimulate the conversion of scientific research from the lab into products needed by both the autism and medical communities, more rapidly and effectively.

"There is an urgent need for autism therapies, medications and devices now, and we are committed to leading both the research and the developments that will benefit the thousands of people who struggle with autism every day," stated Autism Speaks Chief Science Officer Geraldine Dawson, Ph.D., who will chair DELSIA's independent board of managers. "Autism Speaks has funded important research that holds great promise for delivering more effective ways to diagnose and treat autism and it's crucial that we apply what we are learning in the lab to real world solutions that can improve the lives of people living with autism today."

DELSIA will help to advance Autism Speaks' mission by accelerating the development of medicines, treatments, diagnostic tools, therapeutic technologies and devices, and other products that originate from breakthroughs in autism research. DELSIA provides a model of venture philanthropy to take ground-breaking research being done in the lab and facilitate development of those products. While Autism Speaks already invests in scientific research that produces papers for publication or for presentation at professional conferences, this next generation philanthropy will produce medical and non-medical treatments, products and devices to be directly used by the community.

"It's necessary to engage partners from the for-profit sector in order to realize the real-world value promised in the scientific breakthroughs we read about in papers every day," explained DELSIA President Robert H. Ring, Ph.D. Dr. Ring also serves as Autism Speaks Vice President for Translational Research. "With the formation of DELSIA, we have created a model for funding to ensure that development activity by DELSIA's commercial partners is squarely aligned to address unmet needs of our community."

DELSIA will utilize scientific, legal, regulatory and business expertise to identify and fund only the most promising development opportunities. As an affiliate of Autism Speaks, DELSIA will operate with separate governance and accounting, but will operate exclusively on funding provided through awards from Autism Speaks and will not be involved in its own fundraising. The DELSIA board of managers, however, will include some individuals familiar with the operations and mission of Autism Speaks, Gary Goldstein and Adrian Jones, who will also remain on the Autism Speaks board of directors.

DELSIA's partnerships with entrepreneurial organizations will include terms for sharing a portion of positive outcomes, such as royalties. The goal of DELSIA is to create better products that will make a difference, not to create profits. Any positive returns will be converted directly into new awards aimed at creating additional products that can be of immediate benefit to people with autism.


'/>"/>
Contact: Jane E. Rubinstein
jrubinstein@rubenstein.com
212-843-8287
Autism Speaks
Source:Eurekalert  

Related medicine news :

1. An Early Start for Your Child with Autism
2. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
3. Researchers Find Gene Mutations That May Be a Key to Autism
4. Pregnancy Length May Influence Severity of Autism
5. Children Born to Obese Moms May Face Higher Autism Risk: Study
6. Online Tool Could Diagnose Autism Quickly, Developers Say
7. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
8. In Mice, Drug Reverses Symptoms of Condition Linked to Autism
9. Study of half siblings provides genetic clues to autism
10. Genes Associated With Autism Also Related to Schizophrenia
11. Publication Bias Casts Doubt on Value of Antidepressants for Autism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Autism Speaks creates Delivering Scientific Innovation for Autism LLC
(Date:12/8/2016)... , ... December 08, 2016 , ... Vida ... an $18M Series B led by Canvas Ventures . Other investors include Nokia ... scale its mobile platform to serve more consumers who are managing chronic conditions ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... offices headquartered in Jefferson County, is announcing the launch of a charity drive ... The number of homeless women and children in Birmingham has grown steadily since ...
(Date:12/8/2016)... Louis, MS (PRWEB) , ... December 08, 2016 , ... ... that serve commercial and residential clients in and around the Hancock County area, is ... for the Hancock County Food Pantry. , The Hancock County Food Pantry has worked ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... with the announcement that it is one of the early adopters completing EU-U.S. Privacy ... Framework is designed to provide companies on both sides of the Atlantic with a ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kenall Manufacturing, ... new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that ... amount of light where and when it’s needed. , A 2’ x ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... SOUTH SAN FRANCISCO, Calif. , Dec. 8, ... engineered nuclease technology to develop novel antiviral therapeutics, ... , M.D., as chief executive officer and a ... "Dirk is an incredibly experienced executive with a ... companies," said Stephen Quake, D.Phil., founder of Agenovir, ...
(Date:12/8/2016)... N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. (NYSE: ... of $18,800,000, or $0.45 per diluted share, on a 22.1% ... quarter ended October 31, 2016. This compares with net income ... $153,779,000 for the first quarter ended October 31, 2015. ... quarter ended October 31, 2016 to $21,323,000, or $0.51 per ...
(Date:12/8/2016)... 8, 2016 Stock-Callers.com revisits the ... distribution, and marketing of pharmaceutical drug products. Companies in ... and expiration. Additionally, these firms typically have dividend yields ... whole. Up for review this morning are: Novo Nordisk ... (NASDAQ: SGYP ), Pernix Therapeutics Holdings Inc. ...
Breaking Medicine Technology: